Related Experiment Videos
[Josamycin in bronchopulmonary and otorhinological diseases in pediatrics]
Insights
Josamycin effectively treated pediatric respiratory and ear infections in a small study. This macrolide antibiotic showed high efficacy with minimal side effects, making it a promising option for children.
Area of Science:
- Pharmacology
- Pediatrics
- Infectious Diseases
Context:
- Bronchopulmonary and otorhinological infections are common in children.
- Macrolide antibiotics are frequently used for respiratory tract infections.
- Evaluating newer antibiotics for pediatric use is crucial.
Purpose:
- To assess the efficacy and safety of josamycin in treating pediatric bronchopulmonary and otorhinological diseases.
- To determine the optimal dosage and treatment duration for josamycin in children.
- To evaluate the side effect profile and patient acceptance of josamycin.
Summary:
- Josamycin was administered to 29 children (2 months to 13 years) with respiratory or ear infections at 30-60 mg/kg/day for an average of 7.7 days.
- 24 children were cured and 5 showed marked improvement, with only 4 experiencing minor, transient gastrointestinal side effects.
- Josamycin demonstrated broad-spectrum activity, including against Mycoplasma and Chlamydia, with low primary resistance rates in Staphylococcus and no cross-resistance with other antibiotic classes.
Impact:
- Josamycin represents a safe and effective treatment option for bacterial respiratory tract infections in children.
- Its favorable side effect profile and palatability enhance treatment adherence in pediatric patients.
- The antibiotic's activity against atypical pathogens and low resistance rates contribute to its therapeutic value.
Abstract:
Josamycin, one of the more recent macrolide antibiotics, was evaluated in 29 children aged from 2 months to 13 years with bronchopulmonary or otorhinological disease. With a daily dose in the range 30 to 60 mg/kg bodyweight, and an average treatment period of 7.7 days, 24 children were cured and 5 markedly improved. In only 4 children were minor side effects, such as gastrointestinal disturbances, observed, which in no case necessitated interruption of therapy. By virtue of its spectrum of activity josamycin seems to be an ideal antibiotic for the treatment of bacterial respiratory tract infections. In addition, josamycin displays a high degree of activity against mycoplasmas and chlamydiae. Only a very low percentage, reported as 6%, of staphylococcal are primarily resistant to the antibiotic, and the rapid development of resistance to other macrolides, has not been reported for josamycin. No cross resistance exists between josamycin and penicillins, cephalosporins, tetracycline or aminoglycosides. These characteristics represents josamycin for the treatment of respiratory tract infections. The pleasant taste of the preparation used in this study ensured its ready acceptance by the children treated.